Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.79 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5345226 | 1.00 | CCR5 (0.79) | CCR5CYP2C9CYP3A4CXCR4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6186243 | 0.99 | CCR5 (0.80) | CCR5CYP2C9CYP3A4CXCR4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4821984 | 0.99 | CCR5 (0.80) | CCR5CYP2C9CYP3A4CXCR4CYP2D6 | |
| Hydrochloric Acid SCHEMBL5346728 | 0.99 | CCR5 (0.80) | CCR5CYP2C9CYP3A4CXCR4CYP2D6 | |
| SCHEMBL5351415 | 0.99 | CCR5 (0.78) | CCR5CYP2C9CYP3A4CXCR4 | |
| Hydrochloric Acid SCHEMBL5343795 | 0.98 | CCR5 (0.78) | CCR5CYP2C9CYP3A4CXCR4 | |
| Hydrochloric Acid SCHEMBL6187101 | 0.97 | CCR5 (0.76) | CCR5CYP2C9CYP3A4CXCR4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6189078 | 0.97 | CCR5 (0.78) | CCR5CYP2C9CYP3A4CXCR4 | |
| SCHEMBL5349298 | 0.96 | CCR5 (0.73) | CCR5CYP2C9CYP3A4CXCR4 | |
| Hydrochloric Acid SCHEMBL6189629 | 0.95 | CCR5 (0.78) | CCR5CYP2C9CYP3A4CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361758-B2 | Crystals of triazaspiro[5.5]undecane derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-22 | — | — | US | claimed |
| US-7262193-B2 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | claimed |
| EP-1378510-B1 | TRIAZASPIRO (5.5) UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2006-06-07 | — | — | EP | claimed |
| US-7053090-B2 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-30 | — | — | US | claimed |
| US-20060052407-A1 | Novel crystals of triazaspiro [5.5] undecane derivative | ONO PHARMACEUTICAL CO,., LTD (JP) | 2006-03-09 | — | — | US | claimed |
| EP-1619194-A2 | Triazaspiro[5.5]undecane derivatives and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | claimed |
| US-20050215557-A1 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-09-29 | — | — | US | claimed |
| EP-1541573-A1 | NOVEL CRYSTALS OF TRIAZASPIRO 5.5 UNDECANE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | claimed |
| US-20040082584-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | claimed |
| EP-1378510-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | claimed |
| US-7361758-B2 | Crystals of triazaspiro[5.5]undecane derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-22 | — | — | US | disclosed |
| US-7262193-B2 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1378510-B1 | TRIAZASPIRO (5.5) UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-7053090-B2 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-30 | — | — | US | disclosed |
| US-20060052407-A1 | Novel crystals of triazaspiro [5.5] undecane derivative | ONO PHARMACEUTICAL CO,., LTD (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1619194-A2 | Triazaspiro[5.5]undecane derivatives and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-20050215557-A1 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-09-29 | — | — | US | disclosed |
| EP-1541573-A1 | NOVEL CRYSTALS OF TRIAZASPIRO 5.5 UNDECANE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20040082584-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1378510-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052407-A1 | Novel crystals of triazaspiro [5.5] undecane derivative | ACKR3, CCR10, CCR9 | CCR5 4/4885CYP2C9 836/4885CYP3A4 1510/4885 |
| US-20040082584-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | ACKR3, CXCR5, CCL11 | CCR5 4/4885CYP2C9 642/4885CYP3A4 641/4885 |
| US-20050215557-A1 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ACKR3, CCL11, CCR7 | CCR5 5/4885CYP2C9 712/4885CYP3A4 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.